Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Top Pharmacy Courses That Rule the Industry

      Top Pharmacy Courses That Rule the Industry

      Farhat Nasim26 March 2019 9:07 AM IST
      New Delhi: A layman normally links pharmacy with those shops that sell medicines and other related products. However, in the professional or academic...
      Saracatinib gets Orphan Drug Designation for idiopathic pulmonary fibrosis

      Saracatinib gets Orphan Drug Designation for idiopathic pulmonary fibrosis

      Farhat Nasim25 March 2019 12:03 PM IST
      The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for saracatinib, a potential new medicine for the treatment of...
      FDA approves new device for treating moderate to severe chronic heart failure in patients

      FDA approves new device for treating moderate to severe chronic heart failure in patients

      Farhat Nasim25 March 2019 11:51 AM IST
      U.S: The U.S. Food and Drug Administration recently approved the Optimizer Smart system for treating patients with chronic, moderate-to-severe heart...
      Alkem Labs gets 8 USFDA observations for St Louis facility

      Alkem Labs gets 8 USFDA observations for St Louis facility

      Farhat Nasim24 March 2019 9:50 AM IST
      The United States Food and Drug Administration (USFDA) had issued eight observations after inspecting the company's manufacturing plant at St Louis...
      Setback: USFDA rejects Sanofi, Lexicon Sotagliflozin for type 1 diabetes

      Setback: USFDA rejects Sanofi, Lexicon Sotagliflozin for type 1 diabetes

      Farhat Nasim24 March 2019 9:45 AM IST
      The decision comes about two months after an FDA advisory panel failed to reach a consensus over whether the once-daily oral drug, sotagliflozin,...
      Sterling Biotech: Accused in Rs 8100 crore loan fraud held in Albania

      Sterling Biotech: Accused in Rs 8100 crore loan fraud held in Albania

      Farhat Nasim23 March 2019 10:05 AM IST
      The ED had ensued a red corner notice against him from the Interpol on March 11. The detention has happened based on this warrant, the officials said....
      Alembic Pharma gets USFDA nod for Azelastine Hydrochloride Ophthalmic Solution

      Alembic Pharma gets USFDA nod for Azelastine Hydrochloride Ophthalmic Solution

      Farhat Nasim23 March 2019 10:00 AM IST
      Alembic Pharma has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Azelastine...
      Jazz Pharma gets USFDA nod to Solriamfetol to treat sleep disorder

      Jazz Pharma gets USFDA nod to Solriamfetol to treat sleep disorder

      Farhat Nasim23 March 2019 9:15 AM IST
      The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).U.S: The U.S. Food and Drug...
      Zydus Cadila gets USFDA nod to Lurasidone Hydrochloride Tablets

      Zydus Cadila gets USFDA nod to Lurasidone Hydrochloride Tablets

      Farhat Nasim22 March 2019 4:59 PM IST
      Zydus Cadila has got final approval from the US Food and Drug Administration (USFDA) to market Lurasidone Hydrochloride Tablets USP in the strengths...
      Lupin launches generic Levothyroxine Sodium tablets

      Lupin launches generic Levothyroxine Sodium tablets

      Farhat Nasim22 March 2019 11:30 AM IST
      Lupin's Levothyroxine Sodium tablet is the generic version of AbbVie Inc's Synthroid tablets, it added. New Delhi: Drug firm Lupin Friday said it has...
      Setback: JnJ now under FDA scanner for Breast Implants

      Setback: JnJ now under FDA scanner for Breast Implants

      Farhat Nasim22 March 2019 11:19 AM IST
      The letter to JnJ's medical aesthetics unit Mentor Worldwide LLC noted "several serious deficiencies" in the company's post-approval study for its...
      USFDA temporarily allows sale of certain BP medicines amid shortage

      USFDA temporarily allows sale of certain BP medicines amid shortage

      Farhat Nasim22 March 2019 9:00 AM IST
      Some generic versions of other ARBs such as valsartan and irbesartan have also been recalled and the agency in January warned of the possibility of...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok